Evaluation of the safety profile of prolonged-release EE/DNG oral contraceptives: a critical appraisal
Recent publications have suggested that a novel prolonged-release formulation of ethinylestradiol (EE) 20 µg and dienogest (DNG) 2 mg offers improved bleeding profiles and minimal impact on coagulation. These conclusions, however, are based on incomplete safety assessments and potentially misleading...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Taylor & Francis Group
2025-12-01
|
| Цуврал: | Gynecological Endocrinology |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.tandfonline.com/doi/10.1080/09513590.2025.2571648 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|